Skip to content

Calcineurin Inhibitor in NEuRoloGically Deceased Donors to Decrease Kidney delaYed Graft Function (CINERGY)

Brain Death | Ischemic Reperfusion Injury | Organ Transplant Failure or Rejection

The investigators hypothesize that preconditioning neurologically deceased organ donors with the calcineurin inhibitor tacrolimus will improve short and long-term transplant survival without causing harm. Organ donors will be randomized to receive either 0.02 mg/kg ideal body weight (IBW) of tacrolimus single infusion or placebo before organ recovery. All corresponding recipients are enrolled and data is collected up to 7 days post-transplant to determine graft function and at 1 year to collect outcomes of vital status, re-transplantation and dialysis. The CINERGY Pilot Trial assesses feasibility for the main trial.

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    18 and up

Participation Criteria

Neurologically deceased donors who meet the inclusion and exclusion criteria will be eligible for participating in this study along with the correlating organ recipients who meet inclusion criteria.

Donor Inclusion Criteria:

* ≥18 years of age;
* Neurologically deceased;
* Consent for deceased organ donation;
* All organ recipients have been identified;
* ≥ 1 kidney allocated to a recipient.

Donor Exclusion Criteria:

* Known hypersensitivity to tacrolimus or polyoxyl 60 hydrogenated castor oil;
* One or more organs allocated to a non-participating transplant program;
* Unlikely access to study drug (e.g., due to supply issues, or pharmacist availability);
* One or more organ recipients has not agreed to receive an organ from a donor participating in the study;
* One or more organs are allocated to a recipient under the age of 18;
* A transplant physician has judged that donor tacrolimus will be unsuitable for an intended recipient.

Recipient Inclusion Criteria

* Organ/Transplant graft originated from a donor enrolled in this study.

No exclusion criteria.

Study Location

Centre universitaire de santé McGill (CUSM)
Centre universitaire de santé McGill (CUSM)
Montréal, Quebec
Canada

Contact Study Team

Centre Hospitalier Universitaire de Montréal
Centre Hospitalier Universitaire de Montréal
Montréal, Quebec
Canada

Contact Study Team

Centre de recherche CHUS
Centre de recherche CHUS
Sherbrooke, Quebec
Canada

Contact Study Team

Centre Hospitalier Universitaire de Québec- Université Laval
Centre Hospitalier Universitaire de Québec- Université Laval
Quebec city, Quebec
Canada

Contact Study Team

L'Institut de Cardiologie de Montréal
L'Institut de Cardiologie de Montréal
Montréal, Quebec
Canada

Contact Study Team

Hôpital Maisonneuve-Rosemont
Hôpital Maisonneuve-Rosemont
Montréal, Quebec
Canada

Contact Study Team

Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ)
Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ)
Québec City, Quebec
Canada

Contact Study Team

Study Sponsored By
Université de Sherbrooke
Participants Required
More Information
Study ID: NCT05148715